Orphazyme deputy chair thinks layoffs could be option after EU disappointment

Biotech company Orphazyme has enough money to survive for a few months following the news of an expected rejection of the company’s drug hope arimoclomol by the EMA’s expert committee, the CHMP. Deputy Chair Bo Jesper Hansen still has hopes for the company’s chances in the US.
Bo Jesper Hansen has been on the board of Orphazyme since 2010, and has witnessed the company go through both ups and downs | Photo: Kåre Viemose
Bo Jesper Hansen has been on the board of Orphazyme since 2010, and has witnessed the company go through both ups and downs | Photo: Kåre Viemose
by CHRISTIAN BUNDGAARD, translated by daniel pedersen

”Just disappointing.”

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading